Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • AstraZeneca Gets CDSCO...

AstraZeneca Gets CDSCO Panel nod to import, market Trastuzumab deruxtecan for breast cancer

Dr. Divya ColinWritten by Dr. Divya Colin Published On 2023-03-16T18:00:26+05:30  |  Updated On 18 March 2023 5:54 AM GMT
AstraZeneca Gets CDSCO Panel nod to import, market Trastuzumab deruxtecan for breast cancer

New Delhi: Granting the local Phase III clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has granted approval to pharmaceutical major AstraZeneca to import and market anti-cancer drug Trastuzumab deruxtecan Concentrate Solution for infusion 100 mg indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.

Advertisement
However, this approval is subject to a condition that the firm should submit the Phase IV clinical trial protocol within 3 months of importing and marketing permission granted.
This came after the drug major AstraZeneca presented the current status of the ongoing clinical trial of Trastuzumab Deruxtecan Powder for Concentrate Solution for Infusion 100mg for import and marketing in India with local Phase III clinical trial waiver.
Advertisement
Trastuzumab Deruxtecan Powder for Concentrate Solution for Infusion 100mg is indicated for treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2- based regimens .
The committee noted that the drug is approved in Japan, US, EU, UK, Israel, Canada, Switzerland, Australia, Singapore, Brazil, Taiwan, Hongkong, UAE, and South Korea.
The committee further highlighted that the drug is indicated for the treatment of life-threatening diseases and there is an unmet medical need in the country.
Trastuzumab deruxtecan is an antibody used to treat certain types of unresectable or metastatic HER-2-positive breast cancer. Trastuzumab deruxtecan is used to treat adults with certain types of HER2-positive or HER2-low breast cancer, HER2-positive stomach cancer or gastroesophageal junction cancer, or non-small cell lung cancer that has a certain mutation in the HER2 gene.
Trastuzumab deruxtecan binds to HER2 on tumour cells, T-DXd undergoes internalization and intracellular linker cleavage by lysosomal enzymes. Upon release, the membrane-permeable DXd enters the nucleus and causes DNA damage and apoptotic cell death.
At the recent SEC meeting for Oncology and Hematology held on 23rd of February 2023, the expert panel reviewed the current status of the ongoing clinical trial of Trastuzumab Deruxtecan Powder for Concentrate for Solution for Infusion 100mg for import and marketing in India which was presented by the drug major AstraZeneca.
After detailed deliberation, the committee recommended the grant of permission to import and market the drug with the waiver of Phase III clinical trial in the country with the condition that the firm should conduct a Phase IV trial in a minimum of 150 subjects.
Accordingly, the committee directed the firm to submit the Phase IV clinical trial protocol within 3 months of importing and marketing permission granted.
Also Read: Akums gets CDSCO panel nod to manufacture, market FDC Alfuzosin HCL,Tadalafil film coated tablets
AstraZeneca cdsco TrastuzumabDeruxtec breast caner 
Dr. Divya Colin
Dr. Divya Colin

    Doctor of Pharmacy

    Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    X